Oliver Höppner
Plus aucun poste en cours
Profil
Oliver Höppner formerly worked at NOXXON Pharma AG, as Commercial Director, BIOTECTID GmbH, as Finance Director in 2009, Drug Response Dx GmbH, as Chief Financial Officer, and GenProfile AG, as Vice President-Finance.
Mr. Höppner received his graduate degree from Technical University of Berlin.
Anciens postes connus de Oliver Höppner
| Sociétés | Poste | Fin |
|---|---|---|
| GenProfile AG | Directeur Financier/CFO | - |
Drug Response Dx GmbH
 Drug Response Dx GmbH BiotechnologyHealth Technology Drug Response Dx GmbH develops biomarker test kit for rheumatoid arthritis treatment. Its product allows users to classify RA patients as responder or non-responder to TNF-alpha blockers. The company was founded by Zoltán Konthur, Jörg Michael Hollidt, Karl Skriner and Joachim Rautter in February 2012 and is headquartered in Hennigsdorf, Germany. | Directeur Financier/CFO | - |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Corporate Officer/Principal | - |
BIOTECTID GmbH
 BIOTECTID GmbH Medical/Nursing ServicesHealth Services BIOTECTID GmbH chronic inflammatory diseases still give sleepless nights, not only to patients, but also to the treating physicians. Diagnosis and treatment in this field is far more difficult than in cases of acute illness. One example of a chronic-inflammatory disease is rheumatoid arthritis, rheumatism of the joints. A prerequisite for accurately effective and compatible therapies here is to precisely locate the site, extent and intensity of the source of inflammation occurring, and its progression in the further course of the disease. In order for physicians to have more success in this field in future, the employees of BIOTECTID have been tackling this problem for many years and have been able to achieve impressive results: Coming from the research field of immunology, they developed a diagnostic agent based on monoclonal antibodies. Through this, they are very familiar with the immune system. The drug is currently in the first of three clinical test phases. It is manufactured and tested at BIOTECTID by a highly qualified workforce, and corresponds to the demanding EU standards of the Directive for Good Manufacturing Practice (GMP). This diagnostic agent forms the basis of routine examinations that will be possible in every nuclear-medical practice. In a few years they want to be able to help rheumatism patients and rheumatologists sleep soundly again. | Directeur Financier/CFO | - |
Formation de Oliver Höppner
| Technical University of Berlin | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
BIOTECTID GmbH
BIOTECTID GmbH Medical/Nursing ServicesHealth Services BIOTECTID GmbH chronic inflammatory diseases still give sleepless nights, not only to patients, but also to the treating physicians. Diagnosis and treatment in this field is far more difficult than in cases of acute illness. One example of a chronic-inflammatory disease is rheumatoid arthritis, rheumatism of the joints. A prerequisite for accurately effective and compatible therapies here is to precisely locate the site, extent and intensity of the source of inflammation occurring, and its progression in the further course of the disease. In order for physicians to have more success in this field in future, the employees of BIOTECTID have been tackling this problem for many years and have been able to achieve impressive results: Coming from the research field of immunology, they developed a diagnostic agent based on monoclonal antibodies. Through this, they are very familiar with the immune system. The drug is currently in the first of three clinical test phases. It is manufactured and tested at BIOTECTID by a highly qualified workforce, and corresponds to the demanding EU standards of the Directive for Good Manufacturing Practice (GMP). This diagnostic agent forms the basis of routine examinations that will be possible in every nuclear-medical practice. In a few years they want to be able to help rheumatism patients and rheumatologists sleep soundly again. | Health Services |
Drug Response Dx GmbH
Drug Response Dx GmbH BiotechnologyHealth Technology Drug Response Dx GmbH develops biomarker test kit for rheumatoid arthritis treatment. Its product allows users to classify RA patients as responder or non-responder to TNF-alpha blockers. The company was founded by Zoltán Konthur, Jörg Michael Hollidt, Karl Skriner and Joachim Rautter in February 2012 and is headquartered in Hennigsdorf, Germany. | Health Technology |
| GenProfile AG |
